Financing ·
On August 5, 2026, NKGen Biotech, Inc. and its subsidiary entered into a Fourth Amendment to their Secured Convertible…
NKGNNKGen Biotech, Inc.
On August 5, 2026, NKGen Biotech, Inc. and its subsidiary entered into a Fourth Amendment to their Secured Convertible Loan Agreement with AlpineBrook Capital GP I Limited. The Lender extended an additional loan of $1,050,500, which includes a $95,500 facilitation fee, resulting in net proceeds of $955,000 to the Borrowers. This debt is documented by a new promissory note convertible into common stock at $0.08 per share. The Company also issued 13,304,114 consideration shares payable over 30 months and an additional warrant exercisable for three times the loan principal divided by the conversion price, at an exercise price of $0.08 per share. A voting agreement was executed to secure shareholder approval for increasing authorized common stock to accommodate these issuances. NKGen Biotech operates in the biotechnology industry.